专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL232210D0 Novel anti-il 13 antibodies and uses thereof 未知
公开(公告)号：IL232210D0
公开(公告)日：2014-05-28
申请号：IL23221014
申请日：2014-04-23
申请人： SEK CHUNG FUNG , MATTHEW MOYLE , MASON LU , CHANGNING YAN , SANJAYA SINGH , DAN HUANG , GENENTECH INC , TANOX INC
IPC分类号： C12Q20060101 , A61K39/395 , C07K16/00 , C07K16/24 , G01N33/53
摘要： The present invention relates to ant-IL-13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

2. 发明专利

IL176042D0 NOVEL ANTI-IL 13 ANTIBODIES AND USES THEREOF 未知
公开(公告)号：IL176042D0
公开(公告)日：2006-10-05
申请号：IL17604206
申请日：2006-05-31
申请人： TANOX INC , SEK CHUNG FUNG , MATTHEW MOYLE , MASON LU , CHANGNING YAN , SANJAYA SINGH , DAN HUANG
IPC分类号： A61K39/395 , C07K20100101 , C07K16/00 , C07K16/24 , G01N33/53
摘要： The present invention relates to ant-IL-13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

3. 发明申请

WO2007128982A3 COMPOSITIONS AND METHODS FOR EPIGENETIC MODIFICATION OF NUCLEIC ACID SEQUENCES IN VIVO 审中-公开
公开(公告)号：WO2007128982A3
公开(公告)日：2007-11-15
申请号：PCT/GB2007/001304
申请日：2007-04-10
申请人： CELLCENTRIC LTD , REIK, Wolf , MORGAN, Hugh , CHAN, Anthony, Chung-Fung
发明人： REIK, Wolf , MORGAN, Hugh , CHAN, Anthony, Chung-Fung
IPC分类号： C12N15/62
摘要： Demethylation of a methylated DNA sequence in a eukaryotic cell is described, utilising a molecule that includes at least a first domain that exhibits a cytidine deaminase activity and at least a second domain that confers either a specific or non-specific DNA binding activity. The molecules of the invention are useful in somatic cell nuclear transfer and also in cancer therapy.

4. 发明申请

WO2004060365A1 COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER 审中-公开
标题翻译：用于治疗肺癌的组合物和方法
公开(公告)号：WO2004060365A1
公开(公告)日：2004-07-22
申请号：PCT/US2003/041785
申请日：2003-12-30
申请人： AMERICAN HEALTH FOUNDATION , CHUNG, Fung-Lung , CONAWAY, C., Clifford , YANG, Yang-Ming
发明人： CHUNG, Fung-Lung , CONAWAY, C., Clifford , YANG, Yang-Ming
IPC分类号： A61K31/21
CPC分类号： A61K31/26 , A61K31/198 , A61K31/21 , A61K38/063 , A61K47/542 , A61K2300/00
摘要： The invention is directed to methods and compositions of inhibiting lung tumorigenesis. Such method involves the administration of an isothiocyanate conjugate at the post-initiation stage of tumor growth, while avoiding the drawbacks of toxicity of the parent compounds.
摘要翻译：本发明涉及抑制肺肿瘤发生的方法和组合物。这种方法涉及在肿瘤生长的起始后期施用异硫氰酸酯缀合物，同时避免母体化合物毒性的缺点。

5. 发明申请

WO2007128982A2 COMPOSITIONS AND METHODS FOR EPIGENETIC MODIFICATION OF NUCLEIC ACID SEQUENCES IN VIVO 审中-公开
标题翻译： VIVO中核酸序列的组合物和方法
公开(公告)号：WO2007128982A2
公开(公告)日：2007-11-15
申请号：PCT/GB2007001304
申请日：2007-04-10
申请人： CELLCENTRIC LTD , REIK WOLF , MORGAN HUGH , CHAN ANTHONY CHUNG-FUNG
发明人： REIK WOLF , MORGAN HUGH , CHAN ANTHONY CHUNG-FUNG
IPC分类号： C12N5/00
CPC分类号： A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K48/00 , C07K2319/09 , C07K2319/80 , C12N9/78 , C12N15/8509 , C12N15/877
摘要： Demethylation of a methylated DNA sequence in a eukaryotic cell is described, utilising a molecule that includes at least a first domain that exhibits a cytidine deaminase activity and at least a second domain that confers either a specific or non-specific DNA binding activity. The molecules of the invention are useful in somatic cell nuclear transfer and also in cancer therapy.
摘要翻译：描述了真核细胞中甲基化DNA序列的脱甲基，其利用包含至少第一结构域的分子，该第一结构域显示胞苷脱氨酶活性，以及至少第二结构域，赋予特异性或非特异性DNA结合活性。本发明的分子可用于体细胞核转移和癌症治疗。

6. 发明授权

US08734801B2 Anti-IL13 antibodies and uses thereof 有权
公开(公告)号：US08734801B2
公开(公告)日：2014-05-27
申请号：US13275684
申请日：2011-10-18
申请人： Sek Chung Fung , Matthew Moyle , Mason Lu , Changning Yan , Sanjaya Singh , Dan Huang
发明人： Sek Chung Fung , Matthew Moyle , Mason Lu , Changning Yan , Sanjaya Singh , Dan Huang
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , A61K2039/55522 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

7. 发明授权

US08372403B2 Humanized anti-factor D antibodies and uses thereof 有权
标题翻译：人源化抗因子D抗体及其用途
公开(公告)号：US08372403B2
公开(公告)日：2013-02-12
申请号：US13461253
申请日：2012-05-01
申请人： Ling-Ling An , Sek Chung Fung , Robert F. Kelley , Henry B. Lowman , Sanjaya Singh , Herren Wu
发明人： Ling-Ling An , Sek Chung Fung , Robert F. Kelley , Henry B. Lowman , Sanjaya Singh , Herren Wu
IPC分类号： A61K39/395 , C07K16/36 , C07K16/00 , C12N15/13 , C12N15/00 , C12N5/10
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/40 , C07K2317/24 , C07K2317/50 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
摘要翻译：本发明涉及人源化抗人因子D单克隆抗体，其核酸和氨基酸序列，携带这些抗体的细胞和载体及其在制备用于治疗与过度或不受控制的疾病和病症的组合物和药物中的用途补体激活。这些抗体可用于疾病的诊断，预防和治疗。

8. 发明申请

US20130024622A1 EVENT-DRIVEN REGENERATION OF PAGES FOR WEB-BASED APPLICATIONS 有权
标题翻译：基于WEB的应用程序的事件驱动再生页
公开(公告)号：US20130024622A1
公开(公告)日：2013-01-24
申请号：US13620396
申请日：2012-09-14
申请人： John H. Martin , Matthew Helgren , Kin-Chung Fung , Mark R. Scheevel
发明人： John H. Martin , Matthew Helgren , Kin-Chung Fung , Mark R. Scheevel
IPC分类号： G06F12/08
CPC分类号： G06F17/30306 , G06F17/30902 , H04L67/2842
摘要： Systems and methods for invalidating and regenerating pages. In one embodiment, a method can include detecting content changes in a content database including various objects. The method can include causing an invalidation generator to generate an invalidation based on the modification and communicating the invalidation to a dependency manager. A cache manager can be notified that pages in a cache might be invalidated based on the modification via a page invalidation notice. In one embodiment, a method can include receiving a page invalidation notice and sending a page regeneration request to a page generator. The method can include regenerating the cached page. The method can include forwarding the regenerated page to the cache manager replacing the cached page with the regenerated page. In one embodiment, a method can include invalidating a cached page based on a content modification and regenerating pages which might depend on the modified content.
摘要翻译：使页面无效和重新生成的系统和方法。在一个实施例中，一种方法可以包括检测包括各种对象的内容数据库中的内容变化。该方法可以包括使无效生成器基于修改生成无效，并将该无效传递给依赖性管理器。缓存管理器可以被通知，缓存中的页面可能会通过页面无效通知修改而无效。在一个实施例中，一种方法可以包括接收页面无效通知并将页面再生请求发送到页面生成器。该方法可以包括重新生成缓存的页面。该方法可以包括将再生页面转发到高速缓存管理器，用再生页替换缓存的页面。在一个实施例中，一种方法可以包括基于内容修改使得缓存的页面无效，并且重新生成可能取决于修改的内容的页面。

9. 发明授权

US08329868B2 Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases 有权
标题翻译：拮抗剂抗Notch3抗体及其在预防和治疗Notch3相关疾病中的应用
公开(公告)号：US08329868B2
公开(公告)日：2012-12-11
申请号：US13353173
申请日：2012-01-18
申请人： Sek Chung Fung , Kang Li , Yucheng Li , Sanjaya Singh , Bin-Bing Stephen Zhou
发明人： Sek Chung Fung , Kang Li , Yucheng Li , Sanjaya Singh , Bin-Bing Stephen Zhou
IPC分类号： C07K14/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K14/705 , C07K16/28 , C07K2317/56 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.
摘要翻译：本发明涉及特异性结合Notch 3并抑制其活化的拮抗剂抗体。本发明包括与包含第一Lin12结构域和第二二聚化结构域的构象表位结合的抗体。本发明还包括这些抗体治疗或预防Notch 3相关疾病或病症的用途。

10. 发明申请

US20120213785A1 ANTI-NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF NOTCH3-RELATED DISEASES 审中-公开
标题翻译：抗坏血酸激动剂抗体及其在治疗缺血性相关疾病中的应用
公开(公告)号：US20120213785A1
公开(公告)日：2012-08-23
申请号：US13453817
申请日：2012-04-23
申请人： Kang Li , Bin-Bing Stephen Zhou , Wenjuan Wu , Sek Chung Fung , Sanjaya Singh
发明人： Kang Li , Bin-Bing Stephen Zhou , Wenjuan Wu , Sek Chung Fung , Sanjaya Singh
IPC分类号： A61K39/395 , A61P25/06 , A61P25/28
CPC分类号： C07K16/30 , A61K39/00 , A61K39/39558 , A61K2039/505 , A61K2039/5152 , C07K16/00 , C07K16/28 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/75 , C07K2319/30 , G01N33/57492 , G01N33/6893
摘要： The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.
摘要翻译：本发明涉及特异性结合Notch 3并激活信号传导的激动剂抗体。本发明包括与包含第一Lin12结构域的表位结合的抗体。本发明还包括这些抗体治疗或预防Notch 3相关疾病或病症的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式